Literature DB >> 34635978

National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies.

Anthony M Villano1, Roberto J Vidri2, Elaine T Vo2, Stephanie H Greco2, Krisha J Howell3, Margaret von Mehren4, Jeffrey M Farma2.   

Abstract

BACKGROUND: Little level 1 evidence exists to guide multimodality treatment in retroperitoneal soft tissue sarcoma (RPS), which may lead to significant variation in therapeutic approaches. This analysis aimed to describe national RPS treatment trends and explore potential variability among low-/high-volume hospitals (LVH/HVHs). PATIENTS AND METHODS: In total, 5992 patients who underwent resection for primary RPS were retrospectively identified in the National Cancer Database (2004-2017). Time trend analyses examined rates of multivisceral resection (MVR), radiation, and chemotherapy use. LVHs were defined as those carrying out fewer than ten resections per year (N = 5433), whereas HVHs were defined as those carrying out ten or more (N = 559). Descriptive statistics and logistic regression models compared trends between groups.
RESULTS: MVR was more frequent at HVHs (63.7% versus 43.5%, p < 0.001). Use of radiation varied widely by hospital volume. HVHs more frequently employed preoperative radiation as compared with LVHs (14.7% versus 8.1%, p < 0.001). Throughout the study period, LVHs increased utilization of preoperative radiation (2.6% to 12.0%, p < 0.001) whereas rates at HVHs remained stable. Overall, LVHs utilized postoperative radiation significantly more frequently as compared with HVHs (14.7% versus 2.7%, respectively, p < 0.001). Postoperative radiation at LVHs remained stable until 2013 and sharply declined thereafter (16.7% to 6.9%, p < 0.001). Rates of postoperative radiation use at HVHs remained lower than those at LVHs at all time points.
CONCLUSIONS: Strategies for resection and radiation use at LVHs have trended towards those of HVHs. Current national implementation of preoperative radiation, MVR, and chemotherapy remains heterogeneous. These findings inform future trial design and support standardization of care.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34635978     DOI: 10.1245/s10434-021-10908-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.

Authors:  Rolf D Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2010-04-29       Impact factor: 41.316

2.  Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma.

Authors:  George Molina; Melissa A Hull; Yen-Lin Chen; Thomas F DeLaney; Karen De Amorim Bernstein; Edwin Choy; Gregory Cote; David C Harmon; John T Mullen; Alex B Haynes
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

3.  Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation.

Authors:  Sean M McBride; Chandrajit P Raut; Michelle Lapidus; Phillip M Devlin; Karen J Marcus; Monica Bertagnolli; Suzanne George; Elizabeth H Baldini
Journal:  Ann Surg Oncol       Date:  2013-02-08       Impact factor: 5.344

Review 4.  Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience.

Authors:  Robert A Zlotecki; Teri S Katz; Christopher G Morris; D Scott Lind; Steven N Hochwald
Journal:  Am J Clin Oncol       Date:  2005-06       Impact factor: 2.339

5.  Long-term Oncologic Outcomes After Neoadjuvant Radiation Therapy for Retroperitoneal Sarcomas.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

6.  Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.

Authors:  William W Tseng; Francesco Barretta; Lorenzo Conti; Giovanni Grignani; Francesco Tolomeo; Markus Albertsmeier; Martin K Angele; Piotr Rutkowski; Jacek Skoczylas; Antonino De Paoli; Federico Navarria; Chandrajit P Raut; Mark Fairweather; Jeffrey M Farma; Carolyn Nessim; Neha Goel; Valerie P Grignol; Samuel J Ford; Kenneth Cardona; Ty Subhawong; Hannah L Tattersall; Rachel M Lee; James S Hu; Margaret von Mehren; Roberta Sanfilippo; Alessandro Gronchi
Journal:  Cancer       Date:  2020-11-18       Impact factor: 6.860

7.  Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma.

Authors:  J T Miura; J Charlson; T C Gamblin; D Eastwood; A Banerjee; F M Johnston; K K Turaga
Journal:  Eur J Surg Oncol       Date:  2015-07-29       Impact factor: 4.424

8.  Preoperative radiotherapy in the management of retroperitoneal liposarcoma.

Authors:  B L Ecker; M G Peters; M T McMillan; A J Sinnamon; P J Zhang; D L Fraker; W P Levin; R E Roses; G C Karakousis
Journal:  Br J Surg       Date:  2016-09-29       Impact factor: 6.939

9.  The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions.

Authors:  Sanjay P Bagaria; Matthew Neville; Richard J Gray; Emmanuel Gabriel; Jonathan B Ashman; Steven Attia; Nabil Wasif
Journal:  Sarcoma       Date:  2018-07-24

10.  Evaluation of Preoperative Chemotherapy or Radiation and Overall Survival in Patients With Nonmetastatic, Resectable Retroperitoneal Sarcoma.

Authors:  Sung Jun Ma; Oluwadamilola T Oladeru; Mark K Farrugia; Rohil Shekher; Austin J Iovoli; Anurag K Singh
Journal:  JAMA Netw Open       Date:  2020-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.